Peroneal and Achilles Tendon Repair Indications With CLARIX® CORD 1K (PATRICC)
A Multi-center, Open Label, Economic Outcome Study Comparing the Recovery of Patients Receiving CLARIX® CORD 1K as an add-on Treatment During Surgical Tendon Repair to Control Patients Receiving Standard of Care Procedures
Peroneal and Achilles tendon tears are common diseases that present challenges to surgeons due to tendon adhesion complications. Functional recovery is compromised by limiting post-operative range of motion, mobility, and can lead to considerable amount of post-operative pain for the patient.
Amniotic membrane tissue has demonstrated clinical success as an anti-inflammatory and anti-scarring agent and promoting wound healing towards regeneration.
Cryopreserved human amniotic membrane and umbilical cord (AM/UC) tissue in the form of CLARIX® CORD 1K has been used to treat over 5000 orthopedic patients. The investigators hypothesize that its use in peroneal and Achilles tendon surgical repair will enhance the overall functional recovery of the patient.
調査の概要
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85037
- Banner Estrella Medical Center
-
Sun City West、Arizona、アメリカ、85375
- Banner Del Webb Medical Center
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28207
- OrthoCarolina Research Institute
-
-
Ohio
-
Westerville、Ohio、アメリカ、43082
- Orthopedic Foot and Ankle Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male and female patients 18 years to 80 years of age
- Confirmed tendon pathology via MRI, if clinically necessary, with planned surgical repair that have failed conservative management (PT) for a minimum of 2 months for chronic and partial thickness tears; acute full thickness tears or tendon rupture immediately eligible.
- Willing to follow the instructions and complete the visits required.
Exclusion Criteria:
- Psychologically unstable
- Acute infections that, in the opinion of the investigator, may complicate healing
- Currently receiving chemotherapy
- Systemic inflammatory arthritis or Rheumatoid arthritis
- Uncontrolled diabetes as measured by A1C>12
- Bleeding disorders
- Unable to provide informed consent
- Has received oral or parenteral corticosteroids or cytotoxic agents for seven consecutive days in the period of 30 days before surgery OR has received a local steroid injection within 7 days of surgery
- Immunocompromised patients
- Active malignancy other than non-melanoma skin cancer
- Untreated alcohol or substance abuse issues at the time of screening
- Pregnant women at the time of randomization
- Currently enrolled or participated in another investigational device, drug, or biological trial within 60 days of screening
- Allergy to amphotericin-B or Dulbecco's Modified Eagle Medium (DMEM).
- Will undergo significant concurrent procedures with the tendon procedures on the affected foot that, in the opinion of the Investigator, may complicate healing or alter the post-operative visit schedule
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:CLARIX® CORD 1K
Applied in addition to standard of care tendon repair surgery.
|
|
|
介入なし:Standard of care tendon repair surgery only
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change from baseline in patient questionnaire describing function limitation (American Orthopaedic Foot and Ankle Society ankle hindfoot score).
時間枠:Baseline and 1 Year
|
Baseline and 1 Year
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Scheffer Tseng, MD, PhD、Tissue Tech Inc.
出版物と役立つリンク
一般刊行物
- Gelberman RH, Manske PR. Factors influencing flexor tendon adhesions. Hand Clin. 1985 Feb;1(1):35-42.
- Adzick NS, Lorenz HP. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann Surg. 1994 Jul;220(1):10-8. doi: 10.1097/00000658-199407000-00003.
- Jaibaji M. Advances in the biology of zone II flexor tendon healing and adhesion formation. Ann Plast Surg. 2000 Jul;45(1):83-92. doi: 10.1097/00000637-200045010-00017.
- Liu J, Sheha H, Fu Y, Liang L, Tseng SC. Update on amniotic membrane transplantation. Expert Rev Ophthalmol. 2010 Oct;5(5):645-661. doi: 10.1586/eop.10.63.
- Swift H. Amnion for leg ulcers. Lancet. 1980 Jun 21;1(8182):1366-7. doi: 10.1016/s0140-6736(80)91819-x. No abstract available.
- Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol. 2004 Jan-Feb;49(1):51-77. doi: 10.1016/j.survophthal.2003.10.004.
- Bouchard CS, John T. Amniotic membrane transplantation in the management of severe ocular surface disease: indications and outcomes. Ocul Surf. 2004 Jul;2(3):201-11. doi: 10.1016/s1542-0124(12)70062-9.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- CR-2010
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。